Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 23, 2014

View Archived Issues

OMP-59R5 proves active against metastatic pancreatic cancer

Metformin treatment regimen active in refractory colorectal cancer

Vivaldi Biosciences signs agreement with NIAID to develop live vaccine against H7N9

Zealand and Boehringer Ingelheim select new lead compound in diabetes collaboration

Nuevolution collaborates with the Institute of Cancer Research and Cancer Research Technology

Advaxis and Biocon to collaborate on novel cancer immunotherapy

Scioderm's epidermolysis bullosa therapy receives E.U. orphan drug designation

Novel agents for macular degeneration prepared at Novartis

EnVivo Pharmaceuticals initiates phase III trial program for encenicline in AD

The Alzheimer's Institute of America discloses new Nampt inhibitors

NICE recommends use of teriflunomide for MS

New ingenol derivatives prepared at Leo Laboratories

FDA issues complete response letter for Feraheme sNDA

Simcere Pharmaceutical R&D synthesizes novel K(v)7.2 channel activators

TotipotentRX and ThermoGenesis report data from phase Ib critical limb ischemia trial

Reata Pharmaceuticals and AbbVie begin phase I study of RTA-408 for NSCLC

Novel endothelial lipase inhibitor XEN-445 raises HDL cholesterol levels

Pfizer discloses novel LRRK2 inhibitors for Parkinson's disease

Companies sign agreements for darbepoetin alfa biosimilar in Japan

Aniona ApS designs new GABA(A) receptor modulators

FDA grants fast track status to BioAlliance's Validive

Generation of allosteric small-molecule phosphatase inhibitors for the treatment of cancer

Janssen forms new group to oversee global public health portfolio

Phase II trial of Prosonix's orally inhaled LAMA for COPD meets primary endpoint

First dose group recruited for phase II trial of THR-18 in acute stroke

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...